“We are thrilled to have worked with so many biopharmaceutical companies that have brought life-saving and life-enhancing medical products to the patients who need them,” said Jim Corrigan, President and CEO of ERT.
PHILADELPHIA (PRWEB) January 08, 2015
ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced that for the second consecutive year, over 50% of the compounds approved by U.S. FDA have utilized the use of ERT’s cardiac safety, respiratory, and/or electronic Clinical Outcome Assessment (eCOA) solutions to capture critical safety and/or efficacy data during clinical development. The approvals were granted to biopharmaceutical companies in 2013 and 2014.
Many biopharmaceutical companies partner with solutions providers in order to demonstrate their new compounds’ safety and efficacy profiles and to meet regulatory requirements for approval. ERT is a leader in the global clinical trials industry, having supported more than 440 new compounds’ access to market by delivering high quality safety and efficacy endpoint data to sponsors and CROs.
“We are thrilled to have worked with so many biopharmaceutical companies that have brought life-saving and life-enhancing medical products to the patients who need them,” said Jim Corrigan, President and CEO of ERT. “We look forward to continuing our relationships with these organizations and to providing innovative solutions to help them determine the safety and efficacy of new medical products in development.”
For additional information on ERT’s proven cardiac safety, respiratory, and eCOA products and services, visit http://www.ert.com/clinical/clinical-endpoints/.
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COAs) – which includes patient, clinician, and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling, and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.